KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Marika CinauseroNoemi LaproviteraGiovanna De MaglioLorenzo GerratanaMattia RiefoloMarianna MacerelliMichelangelo FiorentinoElisa PorcelliniVanessa BuoroFrancesco GelsominoAnna SquadrilliGianpiero FasolaMassimo NegriniMarcello TiseoManuela FerracinAndrea ArdizzoniPublished in: Therapeutic advances in medical oncology (2019)
This study suggests that the analysis of KRAS and ERBB-family gene mutational status is valuable when assessing the clinical practice for the selection of NSCLC patients to treat with PD-1 inhibitors.
Keyphrases
- small cell lung cancer
- clinical practice
- end stage renal disease
- ejection fraction
- newly diagnosed
- genome wide
- tyrosine kinase
- advanced non small cell lung cancer
- squamous cell carcinoma
- copy number
- prognostic factors
- wild type
- gene expression
- brain metastases
- epidermal growth factor receptor
- transcription factor
- patient reported